| Literature DB >> 30268698 |
Gideon M Blumenthal1, Paul A Bunn2, Jamie E Chaft3, Caroline E McCoach4, Edith A Perez5, Giorgio V Scagliotti6, David P Carbone7, Hugo J W L Aerts8, Dara L Aisner9, Jonas Bergh10, Donald A Berry11, Anthony Jarkowski12, Nicholas Botwood13, Darren A E Cross14, Max Diehn15, Nicole L Drezner16, Robert C Doebele2, Collin M Blakely4, Wilfried E E Eberhardt17, Enriqueta Felip18, Luca Gianni19, Steven P Keller20, Patrick J Leavey21, Shakun Malik22, Francesco Pignatti23, Tatiana M Prowell24, Mary W Redman25, Naiyer A Rizvi26, Rafael Rosell27, Valerie Rusch28, Dirk de Ruysscher29, Lawrence H Schwartz30, Rajeshwari Sridhara31, Rolf A Stahel32, Stephen Swisher33, Janis M Taube34, William D Travis35, Patricia Keegan31, Jacinta R Wiens36, Ignacio I Wistuba37, Murry W Wynes36, Fred R Hirsch38, Mark G Kris39.
Abstract
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence. Published by Elsevier Inc.Entities:
Keywords: Induction chemotherapy; Neoadjuvant therapy; Pathologic response; Preoperative therapy; Resectable lung cancer
Mesh：
Substances：
Year: 2018 PMID： 30268698 DOI： 10.1016/j.jtho.2018.09.017
Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609